Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


BISPECIFIC T-CELL ENGAGING ANTIBODIES FOR CANCER THERAPY

  • In: A7 - Cancer immunotherapy: using drugs and cells to exploit our immune systems on Friday, 2 October 2015, 09:00-12:00
  • At: Düsseldorf (Germany) (2015)
  • Type: Presentation
  • By: WOLF, Andreas (Amgen Research Munich, München, Germany)
  • Co-author(s): Andreas Wolf
  • Abstract:

    BiTE™ antibodies are single-chain bispecific antibody constructs with specificity for CD3 on T cells and a selected surface antigen on target cells. By transiently bridging T cells and cancer cells, BiTE™ antibodies are capable to fully activate T cells and to mount a polyclonal T cell response that is no longer restricted by T cell receptor

    ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses